New Risk • Aug 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 40% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$32m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$51.0m market cap, or US$36.0m). Aankondiging • Jul 27
Syntara Limited to Report Q4, 2026 Results on Jul 28, 2026 Syntara Limited announced that they will report Q4, 2026 results on Jul 28, 2026 Aankondiging • Jun 25
Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 8 million. Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 8 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 242,605,411
Price\Range: AUD 0.027
Discount Per Security: AUD 0.00162
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 53,690,885
Price\Range: AUD 0.027
Discount Per Security: AUD 0.00162
Transaction Features: Subsequent Direct Listing Board Change • May 20
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 2 highly experienced directors. CEO, MD & Director Gary Phillips is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. New Risk • May 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 41% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$36m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (AU$47.9m market cap, or US$34.6m). Board Change • May 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 2 highly experienced directors. CEO, MD & Director Gary Phillips is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Aankondiging • Jan 08
Syntara Limited Announces Company Secretary Changes, Effective January 8, 2026 Syntara Limited announced that existing Chief Financial Officer, Mr. Tim Luscombe, has been appointed as Company Secretary of the company, effective January 8, 2026. For the purposes of ASX Listing Rule 12.6, Mr. Tim Luscombe will be the person responsible for communications with ASX in relation to Listing Rule matters. Mr. Cameron Billingsley has notified the Board of his resignation as Company Secretary, effective January 8, 2026. Mr. Billingsley will continue to provide external general counsel services to Syntara. Board Change • Dec 24
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. 2 highly experienced directors. CEO, MD & Director Gary Phillips is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Aankondiging • Oct 01
Syntara Limited, Annual General Meeting, Nov 20, 2025 Syntara Limited, Annual General Meeting, Nov 20, 2025. New Risk • Aug 29
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: AU$7.6m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 24% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$21m net loss in 2 years). Share price has been volatile over the past 3 months (17% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (AU$7.6m revenue, or US$5.0m). Market cap is less than US$100m (AU$43.9m market cap, or US$28.7m). Aankondiging • Apr 30
Syntara Limited to Report Q3, 2025 Results on May 01, 2025 Syntara Limited announced that they will report Q3, 2025 results on May 01, 2025 Aankondiging • Feb 06
Syntara Limited Announces Board Changes Syntara Limited announced that Cameron Billingsley has been appointed as Company Secretary, effective February 6, 2025. Mr. David McGarvey has notified the Board of his resignation as Company Secretary, effective today. Syntara thanks Mr. McGarvey for his significant contribution to the Company for more than 20 years. Aankondiging • Dec 12
Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million. Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 205,971,256
Price\Range: AUD 0.06
Discount Per Security: AUD 0.0036
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 34,275,302
Price\Range: AUD 0.06
Discount Per Security: AUD 0.0036
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,753,442
Price\Range: AUD 0.06
Discount Per Security: AUD 0.0036
Transaction Features: Subsequent Direct Listing Aankondiging • Dec 10
Syntara Limited Announces Positive Interim Data in Phase 2 Study of SNT-5505 in Myelofibrosis Syntara Limited announced positive interim data from its ongoing Phase 2 clinical trial evaluating SNT-5505 (200 mg BID) in combination with ruxolitinib (RUX) for the treatment of myelofibrosis (MF)1. The interim results suggest that SNT-5505 has potential as a breakthrough therapy for MF and are being presented at the 66thAmerican Society of Hematology annual meeting (ASH). Highlights: At 12 weeks of treatment, 46% of evaluable patients3 achieved a 50% improvement in Total Symptom Score (TSS50) which improved to 80% at 38 weeks of treatment. TSS50 is a standard efficacy endpoint used as the primary endpoint in MF clinical trials. 30% of evaluable patients4 achieved a spleen volume reduction (SVR) of 25% and 20% achieved an SVR of 35%. Both levels are considered clinically meaningful, with SVR35 a typical endpoint used in MF clinical trials. Patient symptoms and spleen volume continued to improve over the duration of the interim data which is a novel finding that differentiates SNT-5505 from MF drugs on market and in later stages of development. SNT-5505 is safe & well tolerated with no treatment related serious adverse events noted at this interim stage - viewed together with the excellent safety profile seen in the earlier monotherapy study5 this is emerging as another key differentiator to MF drugs on the market and in development. After receiving data from a subset of patients reaching 52 weeks of treatment by March 2025, the company intends to discuss with the FDA the trial design for a pivotal Phase 2c/3 study. Concurrently, the company will also engage with potential global and regional partners. There were no treatment related serious adverse events (SAEs) attributed to SNT-5505. Substantial symptom relief observed over time: At Week 12 - 46% (6/13) of evaluable patients achieved a 50% reduction in Myelofibrosis Symptom Assessment Form Total Symptom score (TSS50), a benchmark for clinical response recognised by regulatory authorities such as the FDA. At Week 38 - 80% (4/5) of evaluable patients achieved an TSS50. Of the 16 enrolled patients, 12 patients were continuing to receive treatment as of the ASH data cut off. No discontinuations for adverse events were considered related to SNT-5505 treatment. This level of discontinuations in clinical trials is consistent with a patient group with a high disease burden. The Phase 2 trial has been designed to evaluate SNT-5505 in combination with RUX in patients with intermediate-2 or high-risk MF. Aankondiging • Oct 29
Syntara Limited to Report Q1, 2025 Results on Oct 30, 2024 Syntara Limited announced that they will report Q1, 2025 results Pre-Market on Oct 30, 2024 Aankondiging • Sep 30
Syntara Limited, Annual General Meeting, Nov 28, 2024 Syntara Limited, Annual General Meeting, Nov 28, 2024. Aankondiging • Aug 16
Syntara Limited Announces CFO Changes Syntara Limited announced the appointment of Tim Luscombe as Chief Financial Officer (CFO) for Syntara, effective 31 August 2024. Tim replaces Mr. David McGarvey, who is retiring after more than 20 years as the CFO of Syntara, and before that Pharmaxis. David will continue in his role as Company Secretary to the Board. Tim is a Director at Bio101 Financial Advisory (Bio101), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. Tim has more than 10 years of finance and commercial experience working with public and private companies in Australia and abroad. He currently serves as a CFO and Company Secretary for several ASX-listed, public unlisted and private companies. Tim holds a Bachelor of Commerce from the University of Melbourne, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. In addition to his role as Company Secretary Mr. McGarvey will give special attention to concluding financial and legal arrangements associated with the sale of the mannitol business unit. New Risk • Jul 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$15m free cash flow). Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$6.7m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$28.7m market cap, or US$19.1m). New Risk • Jun 15
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$15m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$15m). Currently unprofitable and not forecast to become profitable over next 2 years (AU$6.7m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$34.6m market cap, or US$22.9m). New Risk • Jun 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$8.9m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$29.9m market cap, or US$19.9m). New Risk • May 29
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$11m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$11m). Currently unprofitable and not forecast to become profitable over next 2 years (AU$6.7m net loss in 2 years). Market cap is less than US$100m (AU$25.1m market cap, or US$16.6m). Aankondiging • Apr 24
Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024 Syntara Limited announced that they will report Q3, 2024 results on Apr 30, 2024 New Risk • Feb 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$12m net loss next year). Market cap is less than US$100m (AU$24.7m market cap, or US$16.1m). Aankondiging • Feb 06
Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million. Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 108,392,130
Price\Range: AUD 0.022
Discount Per Security: AUD 0.00022
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 346,153,325
Price\Range: AUD 0.022
Discount Per Security: AUD 0.00022
Transaction Features: Subsequent Direct Listing Aankondiging • Dec 20
Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million. Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 108,400,000
Price\Range: AUD 0.022
Discount Per Security: AUD 0.00022
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 346,200,000
Price\Range: AUD 0.022
Discount Per Security: AUD 0.00022
Transaction Features: Subsequent Direct Listing New Risk • Dec 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$16m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$16m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$3.5m net loss in 2 years). Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (AU$21.7m market cap, or US$14.5m). New Risk • Nov 02
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$16m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$16m). Currently unprofitable and not forecast to become profitable over next 2 years (AU$4.5m net loss in 2 years). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (AU$22.4m market cap, or US$14.4m). New Risk • Oct 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (AU$25.3m market cap, or US$16.1m). Aankondiging • Oct 20
Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis. Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023. Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis on October 19, 2023. New Risk • Oct 06
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.4% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (AU$24.6m market cap, or US$15.6m). Aankondiging • Oct 05
Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis. Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023. Aankondiging • Sep 13
Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023 Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023, at 11:01 AUS Eastern Standard Time. Reported Earnings • Aug 29
Full year 2023 earnings released: EPS: AU$0 (vs AU$0.003 loss in FY 2022) Full year 2023 results: EPS: AU$0. Revenue: AU$19.3m (up 23% from FY 2022). Net loss: AU$11.4m (loss widened 487% from FY 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 1.6% growth forecast for the Pharmaceuticals industry in Australia. Breakeven Date Change • Aug 29
Forecast to breakeven in 2026 The 2 analysts covering Pharmaxis expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$14.7m in 2026. Average annual earnings growth of 44% is required to achieve expected profit on schedule. New Risk • Aug 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 42% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (AU$36.0m market cap, or US$23.3m). Reported Earnings • Feb 12
Second quarter 2023 earnings released: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022) Second quarter 2023 results: AU$0.008 loss per share. Revenue: AU$1.05m (down 62% from 2Q 2022). Net loss: AU$5.82m (loss widened 3.1% from 2Q 2022). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Australia. Aankondiging • Jan 17
Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive Director Pharmaxis Ltd. announced the appointment of healthcare investment professional Hashan De Silva to the Board as a nonexecutive director. Mr. De Silva is an experienced life sciences investment professional. He worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research. Prior to moving into life science investment Mr. De Silva worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals. Mr. De Silva was educated at the University of New South Wales (Bachelor's Degree in Medicine and Master's Degree in Finance) and is a Chartered Financial Analyst. Until December 2022 Mr. De Silva was Head of Healthcare Research at Karst Peak Capital Limited, a Hong Kong and Australian based specialist healthcare fund and is a nonexecutive director of Melbourne and Philadelphia based CurveBeam AI. Mr. De Silva is based in Sydney Australia and commences his role as nonexecutive director on 16 January 2023. Board Change • Nov 17
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Malcolm McComas was the last independent director to join the board, commencing their role in 2003. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 02
First quarter 2023 earnings released First quarter 2023 results: EPS: AU$0.002. Revenue: AU$8.08m (up 41% from 1Q 2022). Net income: AU$943.0k (up AU$4.12m from 1Q 2022). Profit margin: 12% (up from net loss in 1Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is expected to decline by 1.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Australia are expected to grow by 4.2%. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 01
Full year 2022 earnings released Full year 2022 results: Revenue: AU$15.9m (down 33% from FY 2021). Net loss: AU$1.93m (loss narrowed 35% from FY 2021). Over the next year, revenue is expected to shrink by 18% compared to a 142% growth forecast for the pharmaceuticals industry in Australia. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Chairman of the Board Malcolm McComas was the last independent director to join the board, commencing their role in 2003. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 12
Second quarter 2022 earnings: Revenues exceed analyst expectations Second quarter 2022 results: Revenue: AU$2.78m (down 78% from 2Q 2021). Net loss: AU$5.65m (down 212% from profit in 2Q 2021). Revenue exceeded analyst estimates by 2.5%. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Dec 27
Independent Chairman of the Board recently bought AU$113k worth of stock On the 21st of December, Malcolm McComas bought around 1m shares on-market at roughly AU$0.11 per share. This was the largest purchase by an insider in the last 3 months. Malcolm has been a buyer over the last 12 months, purchasing a net total of AU$156k worth in shares. Reported Earnings • Oct 30
First quarter 2022 earnings released: AU$0.007 loss per share The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: AU$5.74m (up 457% from 1Q 2021). Net loss: AU$3.18m (loss narrowed 36% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Jan 30
Revenue misses expectations Revenue missed analyst estimates by 1.5%. Over the next year, revenue is expected to shrink by 5.5% compared to a 92% growth forecast for the Pharmaceuticals industry in Australia. Reported Earnings • Jan 30
Second quarter 2021 earnings released The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: AU$12.6m (up AU$11.0m from 2Q 2020). Net income: AU$5.03m (up AU$9.60m from 2Q 2020). Profit margin: 40% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings. Reported Earnings • Oct 31
First quarter earnings released Over the last 12 months the company has reported total losses of AU$13.2m, with losses narrowing by 28% from the prior year. Total revenue was AU$11.4m over the last 12 months, down 14% from the prior year. 
